Faiyaz Ahmad Khan

Dr. Faiyaz Ahmad Khan

Sidra medicine, Doha, Qatar
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Cell
Verified
Journal Article
Closed access
SPSung-Jun Park
Sung-Jun Park
Faiyaz Ahmad KhanFaiyaz Ahmad Khan
Faiyaz Ahmad Khan
APAndrew Philp
Andrew Philp
KBKeith Baar
Keith Baar
TWTishan Williams
Tishan Williams
JCJay H. Chung
Jay H. Chung

1 April 2014 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
DMDonald H. Maurice
Donald H. Maurice
HKHengming Ke
Hengming Ke
Faiyaz Ahmad KhanFaiyaz Ahmad Khan
Faiyaz Ahmad Khan
YWYousheng Wang
Yousheng Wang
JCJay Chung
Jay Chung
VMVincent C. Manganiello
Vincent C. Manganiello

5 December 2013 in Endocrine Reviews
Verified
Journal Article
Open access
PDF file
MAMonalisa F. Azevedo
Monalisa F. Azevedo
Fabio FauczFabio Faucz
Fabio Faucz
EBEirini Bimpaki
Eirini Bimpaki
AHAnelia Horvath
Anelia Horvath
ILIsaac Levy
Isaac Levy
Constantine A. StratakisConstantine A. Stratakis
Constantine A. Stratakis
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They are critical regulators of the intracellular concentrations of cAMP and cGMP as well as of their signaling pathways and downstream biological effects. PDEs have been exploited pharmacologically for more than half a century, and some of the most successful drugs worldwide today affect PDE function. Recently, mutations in PDE genes have been identified as causative of certain human genetic diseases; even more recently, functional variants of PDE genes have been suggested to play a potential role in predisposition to tumors and/or cancer, especially in cAMP-sensitive tissues. Mouse models have been developed that point to wide developmental effects of PDEs from heart function to reproduction, to tumors, and beyond. This review brings together knowledge from a variety of disciplines (biochemistry and pharmacology, oncology, endocrinology, and reproductive sciences) with emphasis on recent research on PDEs, how PDEs affect cAMP and cGMP signaling in health and disease, and what pharmacological exploitations of PDEs may be useful in modulating cyclic nucleotide signaling in a way that prevents or treats certain human diseases.

1 September 1995 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Faiyaz Ahmad KhanFaiyaz Ahmad Khan
Faiyaz Ahmad Khan
PLPei-Ming Li
Pei-Ming Li
JMJoseph Meyerovitch
Joseph Meyerovitch
BGBarry J. Goldstein
Barry J. Goldstein
Protein-tyrosine phosphatases (PTPases) have been postulated to balance the steady-state phosphorylation and the activation state of the insulin receptor and its substrate proteins. To explore whether PTP1B, a widely expressed, non-receptor-type PTPase, regulates insulin signaling, we used osmotic shock to load rat KRC-7 hepatoma cells with affinity-purified neutralizing antibodies that immunoprecipitate and inactivate the enzymatic activity of recombinant rat PTP1B in vitro. In cells loaded with PTP1B antibody, insulin-stimulated DNA synthesis and phosphatidylinositol 3′-kinase activity were increased by 42% and 38%, respectively, compared with control cells loaded with preimmune IgG (p < 0.005). In order to characterize the potential site(s) of action of PTP1B in insulin signaling, we also determined that insulin-stimulated receptor autophosphorylation and insulin receptor substrate 1 tyrosine phosphorylation were increased 2.2- and 2.0-fold, respectively, and that insulin-stimulated receptor kinase activity toward an exogenous peptide substrate was increased by 57% in the PTP1B antibody-loaded cells. Osmotic loading did not alter the cellular content of PTP1B protein, suggesting that the antibody acts in the cell by sterically blocking catalytic interactions between PTP1B and its physiological substrates. These studies demonstrate that PTP1B has a role in the negative regulation of insulin signaling and acts, at least in part, directly at the level of the insulin receptor. These results also show that insulin signaling can be enhanced by the inhibition of specific PTPases, a maneuver that has potential clinical relevance in the treatment of insulin resistance and Type II diabetes mellitus.

1 December 2006 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YCYoung Hun Choi
Young Hun Choi
SPSunhee Park
Sunhee Park
SHSteven Hockman
Steven Hockman
EZEmilia Zmuda-Trzebiatowska
Emilia Zmuda-Trzebiatowska
FSFredrik Svennelid
Fredrik Svennelid
VMVincent C. Manganiello
Vincent C. Manganiello
Cyclic nucleotide phosphodiesterase 3B (PDE3B) has been suggested to be critical for mediating insulin/IGF-1 inhibition of cAMP signaling in adipocytes, liver, and pancreatic β cells. In Pde3b-KO adipocytes we found decreased adipocyte size, unchanged insulin-stimulated phosphorylation of protein kinase B and activation of glucose uptake, enhanced catecholamine-stimulated lipolysis and insulin-stimulated lipogenesis, and blocked insulin inhibition of catecholamine-stimulated lipolysis. Glucose, alone or in combination with glucagon-like peptide–1, increased insulin secretion more in isolated pancreatic KO islets, although islet size and morphology and immunoreactive insulin and glucagon levels were unchanged. The β3-adrenergic agonist CL 316,243 (CL) increased lipolysis and serum insulin more in KO mice, but blood glucose reduction was less in CL-treated KO mice. Insulin resistance was observed in KO mice, with liver an important site of alterations in insulin-sensitive glucose production. In KO mice, liver triglyceride and cAMP contents were increased, and the liver content and phosphorylation states of several insulin signaling, gluconeogenic, and inflammation- and stress-related components were altered. Thus, PDE3B may be important in regulating certain cAMP signaling pathways, including lipolysis, insulin-induced antilipolysis, and cAMP-mediated insulin secretion. Altered expression and/or regulation of PDE3B may contribute to metabolic dysregulation, including systemic insulin resistance.

1 December 2011 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
EDEva Degerman
Eva Degerman
Faiyaz Ahmad KhanFaiyaz Ahmad Khan
Faiyaz Ahmad Khan
YCYoun Wook Chung
Youn Wook Chung
EGEmilia Guirguis
Emilia Guirguis
BOBilal Omar
Bilal Omar
VMVincent Manganiello
Vincent Manganiello